Brainstorm Cell Therapeutics Stock Investor Sentiment

BCLI Stock  USD 1.73  0.02  1.17%   
Under 62% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
  

Brainstorm Cell Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at benzinga.com         
SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell T...
benzinga news
over six months ago at accesswire.com         
IMPORTANT DEADLINE REMINDER The Schall Law Firm Reminds Investors in Brainstorm Cell Therapeutics In...
news
over a year ago at accesswire.com         
SHAREHOLDER ACTION ALERT The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics In...
news
over a year ago at benzinga.com         
BRAINSTORM SHAREHOLDER ALERT Faruqi Faruqi Securities Litigation Partner James Wilson Encourages Inv...
benzinga news
over a year ago at news.google.com         
2023-12-01 NDAQBCLI Press Release Brainstorm Cell ... - Stockhouse Publishing
Google News at Macroaxis
over a year ago at benzinga.com         
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Co...
benzinga news
over a year ago at benzinga.com         
SHAREHOLDER ALERT The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a...
benzinga news
over a year ago at thelincolnianonline.com         
Brainstorm Cell Therapeutics Coverage Initiated at StockNews.com
news
over a year ago at benzinga.com         
BRAINSTORM CELL ALERT Bragar Eagel Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Be...
benzinga news
over a year ago at benzinga.com         
SHAREHOLDER ALERT Levi Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Act...
benzinga news
over a year ago at benzinga.com         
Glancy Prongay Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ...
benzinga news
over a year ago at news.google.com         
BCLI Investors Have Opportunity to Lead Brainstorm Cell ... - Marketscreener.com
Google News at Macroaxis
over a year ago at hawaiinewsnow.com         
SHAREHOLDER ALERT The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a...
news
over a year ago at hawaiinewsnow.com         
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Co...
news
over a year ago at news.google.com         
Brainstorm Cell Therapeutics, Inc. Is BCLI Stock Worth Buying ... - Stocks Register
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Brainstorm Cell that are available to investors today. That information is available publicly through Brainstorm media outlets and privately through word of mouth or via Brainstorm internal channels. However, regardless of the origin, that massive amount of Brainstorm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Brainstorm Cell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Brainstorm Cell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Brainstorm Cell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Brainstorm Cell alpha.

Brainstorm Cell Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
09/16/2024
2
BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting
09/24/2024
3
Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3
09/30/2024
4
Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3
10/01/2024
5
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn Trial at the 2024 Maxim Healthcare Virtual Summit
10/07/2024
6
Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3
10/10/2024
7
Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3
10/11/2024
8
BrainStorm Cell Therapeutics regains compliance with Nasdaq
10/30/2024
9
Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
11/12/2024
10
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Canada Finance
11/14/2024
11
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis on December 11, 2024
12/02/2024

Complementary Tools for Brainstorm Stock analysis

When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data